Aldesleukin (DB00041) is not only an IL2RB agonist, but also a modulator of IL2RB which is used to induce the adaptive immune responses in renal cell carcinoma treatment. The gene discussed is IL2RB; the disease is hereditary clear cell renal cell carcinoma.